Cargando…
Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
The availability of a new 20-valent pneumococcal conjugate vaccine (PCV) makes it appropriate to assess its cost-effectiveness. This was evaluated by adopting the Italian National Health Service perspective, using a cost consequences Markovian model. The expected effects of vaccination with 20-valen...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784405/ https://www.ncbi.nlm.nih.gov/pubmed/36560441 http://dx.doi.org/10.3390/vaccines10122032 |
_version_ | 1784857803715772416 |
---|---|
author | Polistena, Barbara Icardi, Giancarlo Orsi, Andrea Spandonaro, Federico Di Virgilio, Roberto d’Angela, Daniela |
author_facet | Polistena, Barbara Icardi, Giancarlo Orsi, Andrea Spandonaro, Federico Di Virgilio, Roberto d’Angela, Daniela |
author_sort | Polistena, Barbara |
collection | PubMed |
description | The availability of a new 20-valent pneumococcal conjugate vaccine (PCV) makes it appropriate to assess its cost-effectiveness. This was evaluated by adopting the Italian National Health Service perspective, using a cost consequences Markovian model. The expected effects of vaccination with 20-valent PCV were compared with the administration of 13-valent PCV and 15-valent PCV. Assuming a 100% vaccination of cohorts aged 65–74 years, in the (lifetime) comparison between 20-valent PCV and 13-valent PCV, the former is dominant (lower cost for a better health outcome). A reduction in disease events was estimated: −1208 deaths; −1171 cases of bacteraemia; −227 of meningitis; −9845 hospitalised all-cause nonbacteremic pneumonia cases (NBP) and −21,058 non-hospitalised. Overall, in the Italian population, a total gain of 6581.6 life years and of 4734.0 QALY was estimated. On the cost side, against an increase in vaccinations costs (EUR +40.568 million), other direct health costs are reduced by EUR 48.032 million, with a net saving of EUR +7.464 million. The comparison between 20-valent PCV and 15-valent PCV results in an Incremental Cost-Effectiveness Ratio (ICER) of EUR 66 per life year gained and EUR 91 per QALY gained. The sensitivity analyses confirm the robustness of the results. We can conclude that the switch to 20-valent PCV is a sustainable and efficient investment. |
format | Online Article Text |
id | pubmed-9784405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97844052022-12-24 Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population Polistena, Barbara Icardi, Giancarlo Orsi, Andrea Spandonaro, Federico Di Virgilio, Roberto d’Angela, Daniela Vaccines (Basel) Article The availability of a new 20-valent pneumococcal conjugate vaccine (PCV) makes it appropriate to assess its cost-effectiveness. This was evaluated by adopting the Italian National Health Service perspective, using a cost consequences Markovian model. The expected effects of vaccination with 20-valent PCV were compared with the administration of 13-valent PCV and 15-valent PCV. Assuming a 100% vaccination of cohorts aged 65–74 years, in the (lifetime) comparison between 20-valent PCV and 13-valent PCV, the former is dominant (lower cost for a better health outcome). A reduction in disease events was estimated: −1208 deaths; −1171 cases of bacteraemia; −227 of meningitis; −9845 hospitalised all-cause nonbacteremic pneumonia cases (NBP) and −21,058 non-hospitalised. Overall, in the Italian population, a total gain of 6581.6 life years and of 4734.0 QALY was estimated. On the cost side, against an increase in vaccinations costs (EUR +40.568 million), other direct health costs are reduced by EUR 48.032 million, with a net saving of EUR +7.464 million. The comparison between 20-valent PCV and 15-valent PCV results in an Incremental Cost-Effectiveness Ratio (ICER) of EUR 66 per life year gained and EUR 91 per QALY gained. The sensitivity analyses confirm the robustness of the results. We can conclude that the switch to 20-valent PCV is a sustainable and efficient investment. MDPI 2022-11-28 /pmc/articles/PMC9784405/ /pubmed/36560441 http://dx.doi.org/10.3390/vaccines10122032 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Polistena, Barbara Icardi, Giancarlo Orsi, Andrea Spandonaro, Federico Di Virgilio, Roberto d’Angela, Daniela Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population |
title | Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population |
title_full | Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population |
title_fullStr | Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population |
title_full_unstemmed | Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population |
title_short | Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population |
title_sort | cost-effectiveness of vaccination with the 20-valent pneumococcal conjugate vaccine in the italian adult population |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784405/ https://www.ncbi.nlm.nih.gov/pubmed/36560441 http://dx.doi.org/10.3390/vaccines10122032 |
work_keys_str_mv | AT polistenabarbara costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation AT icardigiancarlo costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation AT orsiandrea costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation AT spandonarofederico costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation AT divirgilioroberto costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation AT dangeladaniela costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation |